Results 101 to 110 of about 2,244 (146)

Comparative Pharmacovigilance Analysis of Selected Cardiotoxicity Signals Associated with Doxorubicin and Epirubicin Based on EudraVigilance Data. [PDF]

J Clin Med
Fiat ES, Butuca A, Dobrea CM, Ghibu S, Vonica RC, Frum A, Morgovan C, Palade NA, Solomon CC, Batar F, Vintila BI, Totan M, Gligor FG.   +12 more
europepmc   +1 more source

Therapeutic Drug Monitoring and Adverse Drug Reactions: From Signal Detection to Prevention. [PDF]

Pharmaceuticals (Basel)
Algharably E, Gundert-Remy U.
europepmc   +1 more source

Digoxin Dosing Errors, Drug Interactions and Off-Label Risks: Insights from an EudraVigilance Disproportionality Analysis. [PDF]

J Clin Med
Fiat ES, Stoicescu L, Popa Ilie IR, Vonica RC, Butuca A, Dobrea CM, Frum A, Morgovan C, Batar F, Solomon CC, Gligor FG.   +10 more
europepmc   +1 more source

Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis

Background: Anifrolumab is a type I interferon receptor antagonist approved for adults with moderate-to-severe systemic lupus erythematosus (SLE). Although clinical trials established its efficacy and expected safety profile, post-marketing analyses ...
Sandalov, Arseniy, Dal, Uğur, Sandalova, Sofya   +2 more
core  

Global Pharmacovigilance of Aesthetic Botulinum Toxin Type A: Analysis of Adverse Event Reports From the USA, Europe, Canada, and Australia. [PDF]

J Cosmet Dermatol
Zargaran A, Zargaran D, Pirayesh A, Woollard A, Mosahebi A.   +4 more
europepmc   +1 more source

Lorazepam during breastfeeding: a pharmacokinetic case report and exploratory pharmacovigilance assessment - a contribution from the ConcePTION project. [PDF]

Front Pharmacol
Shitreh G, Van Neste M, Ceulemans M, Mian P, Yalçın N, Tezel-Yalçın H, Olsen RH, Gade C, Touw D, Annaert P, Smits A, Allegaert K.   +11 more
europepmc   +1 more source

Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Dubrall D, Christ P, Böhme M, Hahn M, Schmid M, Scholl C.   +5 more
europepmc   +1 more source

Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. [PDF]

Int J Mol Sci
Marin RC, Vesa CM, Tit DM, Radu AF, Bungau GS.   +4 more
europepmc   +1 more source

Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a review. [PDF]

Front Drug Saf Regul
D'souza J, Nandave M, Blöchlinger R.
europepmc   +1 more source

The onset of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with the use of decongestant agents: a European pharmacovigilance analysis. [PDF]

Pharmacol Rep
Anatriello A, Cantone A, Pentella C, Vastarella MG, Mascolo A, Capuano A, Rafaniello C.   +6 more
europepmc   +1 more source